These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

244 related items for PubMed ID: 17210464

  • 1. Assessment of 186Re chelate-conjugated bisphosphonate for the development of new radiopharmaceuticals for bones.
    Uehara T, Jin ZL, Ogawa K, Akizawa H, Hashimoto K, Nakayama M, Arano Y.
    Nucl Med Biol; 2007 Jan; 34(1):79-87. PubMed ID: 17210464
    [Abstract] [Full Text] [Related]

  • 2. Development of a rhenium-186-labeled MAG3-conjugated bisphosphonate for the palliation of metastatic bone pain based on the concept of bifunctional radiopharmaceuticals.
    Ogawa K, Mukai T, Arano Y, Ono M, Hanaoka H, Ishino S, Hashimoto K, Nishimura H, Saji H.
    Bioconjug Chem; 2005 Jan; 16(4):751-7. PubMed ID: 16029015
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Preparation of cyclotron-produced 186Re and comparison with reactor-produced 186Re and generator-produced 188Re for the labeling of bombesin.
    Moustapha ME, Ehrhardt GJ, Smith CJ, Szajek LP, Eckelman WC, Jurisson SS.
    Nucl Med Biol; 2006 Jan; 33(1):81-9. PubMed ID: 16459262
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. 188Re-labeled bisphosphonates as potential bifunctional agents for therapy in patients with bone metastases.
    El-Mabhouh A, Mercer JR.
    Appl Radiat Isot; 2005 Apr; 62(4):541-9. PubMed ID: 15701408
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Monoclonal antibodies labeled with rhenium-186 using the MAG3 chelate: relationship between the number of chelated groups and biodistribution characteristics.
    van Gog FB, Visser GW, Klok R, van der Schors R, Snow GB, van Dongen GA.
    J Nucl Med; 1996 Feb; 37(2):352-62. PubMed ID: 8667076
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Phase 1 study of rhenium-186-HEDP in patients with bone metastases originating from breast cancer.
    de Klerk JM, van het Schip AD, Zonnenberg BA, van Dijk A, Quirijnen JM, Blijham GH, van Rijk PP.
    J Nucl Med; 1996 Feb; 37(2):244-9. PubMed ID: 8667053
    [Abstract] [Full Text] [Related]

  • 16. Skeletal uptake and soft-tissue retention of 186Re-HEDP and 153Sm-EDTMP in patients with metastatic bone disease.
    Brenner W, Kampen WU, Kampen AM, Henze E.
    J Nucl Med; 2001 Feb; 42(2):230-6. PubMed ID: 11216521
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Drug composition matters: the influence of carrier concentration on the radiochemical purity, hydroxyapatite affinity and in-vivo bone accumulation of the therapeutic radiopharmaceutical 188Rhenium-HEDP.
    Lange R, de Klerk JMH, Bloemendal HJ, Ramakers RM, Beekman FJ, van der Westerlaken MML, Hendrikse NH, Ter Heine R.
    Nucl Med Biol; 2015 May; 42(5):465-469. PubMed ID: 25662844
    [Abstract] [Full Text] [Related]

  • 20. [186Re]HEDP in the palliation of painful bone metastases from cancers other than prostate and breast.
    Minutoli F, Herberg A, Spadaro P, Restifo Pecorella G, Baldari S, Aricò D, Altavilla G, Baldari S.
    Q J Nucl Med Mol Imaging; 2006 Dec; 50(4):355-62. PubMed ID: 17043634
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.